Sun Pharma Q2 FY27 Profit Falls 36% Despite Strong Specialty Drug Sales

Sun Pharma Reports Lower Quarterly Profit Despite Strong Revenue Growth

Sun Pharmaceutical Industries Limited reported a 36.2% year-on-year decline in consolidated net profit to approximately ₹1,989 crore for the second quarter of financial year 2026–27, as exceptional expenses related to its proposed Organon acquisition and a US antitrust litigation settlement weighed on reported earnings.

India's largest pharmaceutical company by revenue announced its financial results on October 30, 2026, for the quarter ended September 30.

Consolidated revenue from operations increased 11.9% to ₹16,198.7 crore, compared with approximately ₹14,478 crore in the corresponding quarter of the previous financial year.

The revenue expansion was supported by strong performance in the Indian pharmaceutical market, emerging economies and the company's global innovative medicines business.

However, reported profitability was affected by exceptional charges totalling ₹1,268.8 crore.

These included ₹346.2 crore in costs associated with Sun Pharma's proposed acquisition of US-based Organon & Co. and ₹922.7 crore relating to the settlement of a US generic pharmaceutical pricing antitrust litigation matter.

Excluding exceptional items, adjusted net profit increased approximately 1.4% year-on-year to ₹3,162 crore.

Global innovative medicines sales rose 6.9% to $356 million, demonstrating continued demand for the company's specialty pharmaceutical portfolio.

The results highlight the contrast between Sun Pharma's underlying business growth and the temporary financial impact of major corporate transactions and legal settlements.

Key Highlights of Sun Pharma Q2 FY27 Results

The results indicate that revenue growth remained healthy, while exceptional expenses and pressure on operating margins reduced reported earnings.

₹1,269 Crore Exceptional Charges Drive Profit Decline

Sun Pharma recognised exceptional charges of approximately ₹1,268.8 crore during the September quarter.

The expenses were associated with two major developments: the proposed Organon acquisition and a settlement relating to US pharmaceutical pricing litigation.

The litigation settlement represented the larger portion of the exceptional charges.

The acquisition-related expenses included professional fees and financing arrangement costs associated with the proposed Organon transaction.

These expenses materially reduced reported net profit.

However, the exceptional charges should be distinguished from the company's recurring pharmaceutical manufacturing, research and commercial operations.

The distinction is important when evaluating the underlying performance of Sun Pharma's businesses.

Organon Acquisition Costs Reach ₹346 Crore

Sun Pharma recorded ₹346.16 crore in expenses associated with its proposed acquisition of Organon & Co.

The costs include due diligence, legal and filing fees, financing commitment charges, syndication fees and other transaction-related expenditure.

Such expenses arise when companies undertake large acquisitions requiring extensive legal, financial and regulatory work.

The Organon transaction represents one of the most significant international acquisitions proposed by an Indian pharmaceutical company.

Sun Pharma announced the agreement earlier in 2026, valuing Organon at an enterprise value of approximately $11.75 billion.

The proposed acquisition is intended to strengthen Sun Pharma's global pharmaceutical presence, particularly in the United States.

However, the transaction remains subject to completion requirements.

Sun Pharma has indicated that additional acquisition-related expenses may be recognised in subsequent financial periods as the transaction progresses.

US Antitrust Settlement Adds ₹923 Crore Charge

The largest exceptional expense was associated with a US antitrust litigation settlement.

Sun Pharma disclosed that its subsidiaries, including Sun Pharmaceutical Industries Inc., Taro Pharmaceutical Industries Limited and Taro Pharmaceuticals USA Inc., entered into a settlement agreement on September 10, 2026.

The agreement relates to litigation involving alleged pricing practices in the US generic pharmaceutical industry.

The settlement resulted in a charge of approximately ₹922.67 crore, including legal costs.

Sun Pharma also recognised a corresponding tax benefit of ₹95.34 crore during the quarter.

The expense contributed significantly to the decline in reported profitability.

The settlement relates to historical legal proceedings and should be assessed separately from the company's current pharmaceutical sales performance.

Adjusted Net Profit Rises to ₹3,162 Crore

Excluding exceptional items, Sun Pharma reported adjusted net profit of approximately ₹3,162 crore.

This compares with approximately ₹3,118 crore in the corresponding quarter of FY26.

The increase represents around 1.4% year-on-year growth.

Adjusted earnings provide an additional perspective on the company's performance after excluding specified exceptional expenses.

However, the adjusted growth rate was considerably lower than revenue growth.

This reflects pressure on operating profitability during the quarter.

Investors should consider both reported and adjusted earnings.

Reported net profit reflects the full financial impact of recognised expenses, while adjusted profit can help assess recurring business performance.

Revenue Increases Nearly 12% to ₹16,199 Crore

Sun Pharma reported consolidated revenue from operations of ₹16,198.7 crore during Q2 FY27.

Revenue increased approximately 11.9% from the corresponding quarter of the previous financial year.

The performance exceeded analysts' average revenue estimate of approximately ₹15,825 crore.

Growth was driven primarily by the Indian pharmaceutical business and international markets outside the United States.

The company's innovative medicines portfolio also contributed positively.

Revenue expansion demonstrates the strength of Sun Pharma's diversified business model.

However, the company's profitability remained affected by differences in product mix, operating expenses and exceptional charges.

India Formulations Business Grows 17.3%

Sun Pharma's Indian formulations business delivered strong growth during the quarter.

Sales increased 17.3% year-on-year to ₹5,552.3 crore.

India accounted for approximately 34.5% of the company's consolidated sales.

The performance reinforced the domestic market's importance to Sun Pharma's overall business.

Growth was supported by the company's established branded pharmaceutical portfolio and new product introductions.

Sun Pharma launched 14 products in India during the September quarter.

For the first half of FY27, the company introduced 19 products.

The domestic business remains a major source of revenue growth and operating stability.

Sun Pharma Maintains Leadership in Indian Pharmaceutical Market

Sun Pharma retained its position as India's largest pharmaceutical company in the domestic formulations market.

According to September 2026 moving annual total data from Pharmarack, the company's market share increased to 8.6% from 8.3%.

The improvement reflects its strong position across multiple therapeutic categories.

The company also ranked first by prescriptions in 12 doctor categories, according to SMSRC data.

Its domestic portfolio includes treatments across chronic and acute therapeutic areas.

A broad product range and established distribution network support its presence in the Indian market.

Continued growth will depend on product innovation, prescription demand, competition and market conditions.

Specialty Medicine Sales Increase 6.9% to $356 Million

Sun Pharma's global innovative medicines business recorded sales of $356 million during the quarter.

This represented growth of 6.9% year-on-year.

Innovative medicines accounted for approximately 21.1% of total sales.

The business includes specialty treatments across dermatology, oncology and other therapeutic areas.

Sun Pharma has been expanding its innovative medicines portfolio to diversify revenue beyond conventional generic pharmaceuticals.

Specialty medicines can offer differentiated commercial opportunities because they often involve complex development programmes and specialised treatment requirements.

However, their commercial performance depends on regulatory approvals, clinical adoption, reimbursement arrangements and competition.

The quarterly growth demonstrates continued demand, although performance varied across individual products and markets.

Ilumya Receives US Approval for Psoriatic Arthritis

A major product development during the quarter was the US approval of Ilumya for the treatment of adults with active psoriatic arthritis.

Ilumya is part of Sun Pharma's innovative medicines portfolio.

The additional indication expands the product's potential clinical applications in the United States.

Regulatory approval for a new indication can create opportunities to reach additional eligible patients.

However, commercial success depends on physician adoption, reimbursement coverage and competition from existing therapies.

Sun Pharma's management also acknowledged slower growth in Ilumya sales in the US market.

The company identified a combination of market conditions and commercial execution factors.

Management indicated that corrective measures were being implemented to address these challenges.

Unloxcyt Receives Important Oncology Treatment Recommendation

Sun Pharma also reported a positive development for Unloxcyt, a treatment associated with advanced cutaneous squamous cell carcinoma.

The product received a preferred recommendation from the National Comprehensive Cancer Network for the relevant treatment setting.

Such recommendations can influence clinical treatment decisions and support awareness among healthcare professionals.

However, inclusion in clinical guidelines does not automatically guarantee commercial adoption.

The product's future sales will depend on patient eligibility, clinical use, access and reimbursement.

The development nevertheless strengthens Sun Pharma's position in specialty oncology treatments.

It also reflects the company's strategy of expanding its innovative medicines portfolio.

US Formulation Sales Decline 8.2%

Sun Pharma's US formulation business reported sales of $455 million during Q2 FY27.

This represented a decline of approximately 8.2% year-on-year.

The reduction was primarily associated with lower sales of generic lenalidomide.

The product had contributed significantly to US revenue in earlier periods.

However, increasing competition and changes in market dynamics have reduced its contribution.

Despite the year-on-year decline, US formulation sales increased approximately 6.5% sequentially.

The company also launched five generic products in the US during the quarter.

The sequential improvement suggests some recovery in the business, although the year-on-year comparison remained weak.

Generic Lenalidomide Erosion Affects US Performance

Generic lenalidomide has been an important product for Sun Pharma's US business.

However, its sales contribution has declined as market conditions changed.

Generic pharmaceutical markets are often characterised by increasing competition after multiple manufacturers enter a product category.

This can result in lower selling prices and reduced profitability.

Sun Pharma's US business has been affected by this dynamic.

The company is seeking to offset pressure through new generic launches and expansion of its specialty portfolio.

The proposed Organon acquisition is also intended to strengthen its international commercial presence.

However, replacing revenue from high-contribution products can take time.

Emerging Markets Revenue Grows 7.6%

Sun Pharma reported emerging markets formulation sales of $350 million during the quarter.

This represented growth of approximately 7.6% year-on-year.

Emerging markets remain an important component of the company's international business.

These markets provide opportunities for growth through branded formulations, generic medicines and broader healthcare access.

However, performance can be influenced by currency movements, regulatory requirements and local market conditions.

Sun Pharma's diversified geographic presence helps reduce dependence on any single international market.

The growth in emerging markets contributed positively to consolidated revenue.

Rest-of-World Sales Increase 3.1%

Sun Pharma's rest-of-world formulation business reported sales of approximately $241 million.

The increase represented 3.1% year-on-year growth.

The segment includes international markets outside India, the United States and the company's designated emerging markets group.

Performance across these markets depends on product registrations, pricing, distribution and competitive conditions.

The growth contributed to Sun Pharma's overall international revenue.

However, the relatively modest increase compared with India highlights differences in regional demand and business conditions.

EBITDA Rises 4.8% but Margin Contracts

Sun Pharma reported EBITDA of approximately ₹4,743.9 crore during Q2 FY27.

This compares with approximately ₹4,527 crore in the corresponding quarter of FY26.

The increase represents 4.8% year-on-year growth.

However, EBITDA margin declined to 29.3% from 31.3%.

The two-percentage-point contraction indicates that operating earnings grew more slowly than revenue.

Management noted that the previous year's profitability benefited from generic lenalidomide sales in the United States.

The reduction in that product's contribution affected the year-on-year margin comparison.

Product mix and operating expenditure also influence profitability.

The company will need to sustain growth in higher-value medicines while managing costs to support margin recovery.

Research and Development Spending Reaches ₹778 Crore

Sun Pharma reported research and development expenditure of ₹778.4 crore during the quarter.

This represented approximately 4.8% of sales.

Innovative medicines research accounted for 32.4% of total R&D spending.

The company continues investing in new pharmaceutical products, clinical development and regulatory activities.

Research expenditure is particularly important for innovative medicines because development programmes can require substantial time and financial resources.

Sun Pharma's R&D spending during the quarter was below management's intended level.

Chairman Dilip Shanghvi indicated that expenditure could increase during the second half of FY27.

The timing of research spending may therefore influence operating expenses in subsequent quarters.

Organon Acquisition Expected to Close in Q4 FY27

Sun Pharma continues progressing with its proposed acquisition of Organon & Co.

The transaction is valued at approximately $11.75 billion on an enterprise value basis.

Management indicated that integration planning is proceeding according to schedule.

Regulatory approvals have been obtained in most relevant jurisdictions.

The company expects the transaction to close during the fourth quarter of FY27.

However, the acquisition remains subject to outstanding approvals and closing requirements.

The transaction could significantly expand Sun Pharma's international operations.

Its eventual financial impact will depend on financing arrangements, integration costs, operational synergies and the performance of the acquired business.

Organon Deal Could Transform Sun Pharma's Global Portfolio

The proposed acquisition of Organon represents a major strategic development for Sun Pharma.

Organon has an established international pharmaceutical business with operations across multiple therapeutic categories.

The combination could expand Sun Pharma's global commercial infrastructure and product portfolio.

It may also create opportunities for operational integration and geographic diversification.

However, large international acquisitions involve significant financial and execution risks.

These include acquisition financing, regulatory compliance, organisational integration and potential changes in market conditions.

Sun Pharma will need to manage these factors carefully.

The company has already recognised substantial transaction-related expenses, and further costs are expected before completion.

Management Maintains FY27 Revenue Growth Guidance

Despite reporting double-digit revenue growth during the first half of FY27, Sun Pharma maintained its existing full-year guidance.

Management continues to expect high-single-digit revenue growth for the financial year.

The decision reflects a measured outlook despite strong performance in the domestic business.

Several factors may influence revenue growth during the remaining quarters.

These include US generic competition, specialty medicine sales, emerging market demand and the timing of the Organon transaction.

The company also expects research and development expenditure to increase during the second half.

Management's decision to retain guidance indicates that it is not assuming the first-half growth rate will necessarily continue unchanged.

Kirti Ganorkar Highlights Strength in India and International Markets

Kirti Ganorkar, Managing Director of Sun Pharma, attributed the company's quarterly performance to strong momentum in India, emerging markets and rest-of-world operations.

The company continues to focus on expanding its specialty portfolio and strengthening its position across major pharmaceutical markets.

Management highlighted regulatory and clinical developments involving Ilumya and Unloxcyt.

These developments support the company's strategy of building a differentiated innovative medicines business.

At the same time, Sun Pharma is addressing pressure in the US generic market.

The company's ability to balance established formulations revenue with specialty medicine growth will remain important for future profitability.

Investors Assess Reported Profit Against Underlying Performance

Sun Pharma's quarterly results present two different perspectives on profitability.

Reported net profit declined sharply because of exceptional expenses.

However, revenue increased nearly 12%, while adjusted net profit remained slightly above the previous year's level.

This distinction is important for investors evaluating the company's financial position.

The Organon acquisition costs and US litigation settlement materially affected the quarter's reported earnings.

At the same time, the decline in EBITDA margin indicates that the company also faces operating challenges.

Investors will monitor the sustainability of India growth, specialty medicine sales and the performance of the US business.

The proposed Organon acquisition will remain another major factor influencing expectations.

Sun Pharma Shares React Positively to Earnings

Sun Pharma shares attracted buying interest following the earnings announcement.

The stock rose during trading after investors assessed the company's revenue growth, specialty medicine performance and underlying profitability.

Market participants also considered management's comments on the Organon transaction.

The positive reaction suggests that investors placed importance on operating performance beyond the reported decline in net profit.

However, share price movements can reflect multiple factors, including market conditions and changes in investor expectations.

The company's future valuation will depend on earnings growth, margins, acquisition execution and financial performance.

Conclusion

Sun Pharmaceutical Industries' Q2 FY27 results reflected strong business growth alongside a substantial decline in reported profitability.

Consolidated net profit fell approximately 36.2% to ₹1,989 crore, primarily because of exceptional charges totalling ₹1,268.8 crore.

These included ₹346.2 crore in Organon acquisition-related expenses and ₹922.7 crore associated with a US antitrust litigation settlement.

Despite the charges, revenue increased 11.9% to ₹16,198.7 crore.

India formulation sales grew 17.3%, while global innovative medicines revenue increased 6.9% to $356 million.

However, US formulation sales declined 8.2%, and EBITDA margin contracted to 29.3%.

The company continues to expand its specialty medicine portfolio and expects its proposed Organon acquisition to close during the fourth quarter of FY27.

Going forward, Sun Pharma's performance will depend on sustaining domestic growth, improving US operations, managing research expenditure and successfully completing the Organon transaction.